Taysha Gene Therapies, Inc. (TSHA) P/S ratio

P/S ratio today
130.9×

Taysha Gene Therapies, Inc. (TSHA) trades at 130.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 179.9×. That is 246.5% higher than the 51.9× of fiscal 2024. Figures as of 18 Nov 2026, 05:10 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
130.9×
P/S ratio, fiscal 2025
179.9×
Change on fiscal 2024
+246.5%
Highest on record
179.9×fiscal 2025
Lowest on record
13.3×fiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Taysha Gene Therapies, Inc. P/S ratio, in more detail

Today's figure is 27.3% below the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 179.9× in fiscal 2025 and the lowest 13.3× in fiscal 2023. Today's P/S ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 45.8×.

History · 4 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Taysha Gene Therapies, Inc. P/S ratio, year by year

Taysha Gene Therapies, Inc. (TSHA) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today130.9×—$4.00—
2025179.9× 246.5% up$5.50$0.03
202451.9× 290.4% up$1.73$0.03
202313.3× 66.5% down$1.77$0.13
202239.7×—$2.26$0.06
2021——$11.65—
2020——$26.54—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on TSHA

Taysha Gene Therapies, Inc., figure by figure

Taysha Gene Therapies, Inc. (TSHA) overview: price, valuation and scorecard

Taysha Gene Therapies, Inc. P/S ratio: questions and answers

What is Taysha Gene Therapies, Inc.'s P/S ratio?

Taysha Gene Therapies, Inc. (TSHA) trades at 130.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 179.9×. That is 246.5% higher than the 51.9× of fiscal 2024.

Is Taysha Gene Therapies, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 75% of the 4 fiscal year-ends on record; their median is 45.8×.

What are the highest and lowest P/S ratio figures on record for Taysha Gene Therapies, Inc.?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 179.9× in fiscal 2025 and the lowest 13.3× in fiscal 2023.

How is Taysha Gene Therapies, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Taysha Gene Therapies, Inc. (TSHA) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/TSHA/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.